Table 3.

Characteristics of non-RCT included in sensitivity analysis of the RR for failure to induce remission (complete or partial)a

StudyYearFollow-Up (mo)Method of Treatment AllocationMMFCYC
Dosage (g/d)Patients (n)Treatment FailuresDosagePatients (n)Treatment Failures
Hu et al.(12)20026MMF for refractory LN12370.75 to 1 g/m2 intravenously2312
Lin et al. (20)200212MMF for those able to afford1.51040.6 g intravenously every 1 to 2 wk74
  • a LN, lupus nephritis.